Phase 3 study for people with Lymphoma

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 13 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Regeneron Pharmaceuticals
Registry number NCT06091254
Started 12 December 2023 Today 16 October 2026 Estimated completion 7 February 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Ingham Institute Liverpool NSW Recruiting
Icon Cancer Centre - Wesley Auchenflower QLD Completed
Flinders Medical Centre Bedford Park SA Recruiting
Monash Health Clayton VIC Recruiting
Epworth Freemasons East Melbourne VIC Recruiting
Alfred Hospital and Monash University Melbourne VIC Recruiting
St Vincents Hospital Melbourne Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 13 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 822

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

1. Diagnosis of Cluster of Differentiation 20\^+ (CD20\^+) FL Grade 1-3a, stage II bulky or stage III / IV

2. Need for treatment as described in the protocol

3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

5. Adequate bone marrow function and hepatic function, as described in the protocol

Key Exclusion Criteria:

1. Central Nervous System (CNS) lymphoma or leptomeningeal lymphoma

2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma

3. Waldenström Macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma

4. Treatment with any systemic anti-lymphoma therapy

5. Infections and allergy/hypersensitivity to study drug or excipient, as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Dates on the record

Started 12 December 2023
Estimated completion 7 February 2028
Registry last updated 6 October 2026
Checked by Voxsanity 13 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 6 October 2026.
  • This page last checked by Voxsanity: 13 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.